Biotech RadarJobs updated

COMPANY

ADARx Pharmaceuticals

HQ: San Diego, CA source · adarx.com ↗

Clinical Phase 3

8 open jobs · last seen Oct 23, 2026 · 11 sources

Keywords: RNA therapeutics siRNA Hereditary Angioedema HAE Hereditary Angioedema - Type 1 Hereditary Angioedema - Type 2 IC-MPGN Hypertension Hypertension,Essential Geographic Atrophy Secondary to Age-related Macular Degeneration Immunoglobulin A Nephropathy Complement 3 Glomerulopathy (C3G) IgAN C3G Complement-mediated Kidney Disease IgA Nephropathy Paroxysmal Nocturnal Hemoglobinuria ADX-038 ADX-324 ADX-626 ADX-850

Location: San Diego, CA · source · Oct 12, 2026

Profile checked Oct 10, 2026

8Open jobs$513.2MRaised (2 yrs)9Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Associate Director/Director, Financial Planning & AnalysisSan Diego, CA, San Diego, CA, USSep 30, 2026Oct 11, 2026
Director, Total Rewards & HRISSan Diego, CA, San Diego, CA, USSep 29, 2026Oct 11, 2026
Senior Research Associate, Discovery BiologySan Diego, CA, San Diego, CA, USSep 22, 2026Oct 11, 2026
Executive Assistant (C-Suite)San Diego, CA, San Diego, CA, USSep 12, 2026Oct 11, 2026
Director, Program ManagementSan Diego, CA, San Diego, CA, USSep 8, 2026Oct 11, 2026

See all 8 jobs

Timeline

  1. Raise IPO: $513.2M (total, as published), announced Oct 1, 2026. Source: company release on GlobeNewswire. source ↗
  2. Trial start Phase 2: Chinese Adults With Kidney Disease source ↗
  3. Trial start 3: Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) source ↗
  4. Trial start 2: Phase 2 Study of ADX-038 in Participants With Geographic Atrophy source ↗
  5. Trial start 3: STOP-HAE: A Phase 3 Study of ADX-324 in HAE source ↗
  6. Trial start 2: Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease source ↗
  7. Trial start 1: Phase 1 Study of ADX-626 in Healthy Participants source ↗
  8. Partnership Partnership / licensing announced May 14, 2025. Source: company's own press page. source ↗
  9. Trial start Phase 1: Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension source ↗
  10. Trial start Phase 1/Phase 2: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients source ↗
  11. Trial start Phase 1/Phase 2: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $513.2M. Last 2 years.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT06960213STOP-HAE: A Phase 3 Study of ADX-324 in HAE3RecruitingAug 28, 2025Nov 30, 2027 (estimated)
NCT07081503Phase 1 Study of ADX-626 in Healthy Participants1RecruitingAug 12, 2025Jan 22, 2027 (estimated)
NCT07428499Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)3RecruitingApr 2, 2026Jun 30, 2030 (estimated)
NCT06205628Safety, Tolerability, PK and PD of ADX-850 in Participants With HypertensionPhase 1Active, not recruitingMar 21, 2024Jul 31, 2026 (actual)
NCT06990269Phase 2 Study of ADX-038 in Participants With Geographic Atrophy2RecruitingNov 10, 2025Feb 28, 2030 (estimated)
NCT07522099Chinese Adults With Kidney DiseasePhase 2RecruitingMay 21, 2026Jul 10, 2028 (estimated)
NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease2RecruitingAug 28, 2025Dec 31, 2028 (estimated)
NCT05876312Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) PatientsPhase 1/Phase 2RecruitingAug 7, 2023Mar 31, 2028 (estimated)
NCT05691361Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema PatientsPhase 1/Phase 2Active, not recruitingDec 14, 2022Dec 31, 2027 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Open jobs 8

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Associate Director/Director, Financial Planning & AnalysisSan Diego, CA, San Diego, CA, USSep 30, 2026Oct 11, 2026Senior
Director, Total Rewards & HRISSan Diego, CA, San Diego, CA, USSep 29, 2026Oct 11, 2026Senior
Senior Research Associate, Discovery BiologySan Diego, CA, San Diego, CA, USSep 22, 2026Oct 11, 2026Senior
Executive Assistant (C-Suite)San Diego, CA, San Diego, CA, USSep 12, 2026Oct 11, 2026Mid
Director, Program ManagementSan Diego, CA, San Diego, CA, USSep 8, 2026Oct 11, 2026Senior
Director, Clinical Quality AssuranceSan Diego, CA, San Diego, CA, USJul 31, 2026Oct 11, 2026Senior
Director, CMC-Drug SubstanceSan Diego, CA, San Diego, CA, USApr 16, 2026Oct 11, 2026Senior
Senior Scientist I-II, ConjugationSan Diego, CA, San Diego, CA, USApr 1, 2026Oct 11, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at ADARx Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback